Literature DB >> 35880758

The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.

Jean M Mitchell1, Carole Roan Gresenz2.   

Abstract

BACKGROUND: Vertical and horizontal integration among health care providers has transformed the practice arrangements under which many physicians work.
OBJECTIVE: To examine the influence of type of practice structure, and by implication the financial incentives associated with each structure, on treatment received among men newly diagnosed with low-risk prostate cancer. RESEARCH
DESIGN: We compiled a unique database from cancer registry records from 4 large states, Medicare enrollment and claims for the years 2005-2014 and SK & A physician surveys corroborated by extensive internet searches. We estimated a multinomial logit model to examine the influence of urologist practice structure on type of initial treatment received.
RESULTS: The probability of being monitored with active surveillance was 7.4% and 4.2% points higher for men treated by health system and nonhealth system employed urologists ( P <0.01), respectively, in comparison to men treated by single specialty urology practices. Among multispecialty practices, the rate of active surveillance use was 3% points higher compared with single specialty urology practices( P <0.01). Use of intensity modulated radiation therapy among urologists with ownership in intensity modulated radiation therapy was 17.4% points higher compared with urologists working in small single specialty practices.
CONCLUSIONS: Physician practice structure attributes are significantly associated with type of treatment received but few studies control for such factors. Our findings-coupled with the observation that urologist practice structure shifted substantially over this time period due to mergers of small urology groups-provide one explanation for the limited uptake of active surveillance among men with low-risk disease in the US.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35880758      PMCID: PMC9378464          DOI: 10.1097/MLR.0000000000001746

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  31 in total

1.  The Results Are Only as Good as the Sample: Assessing Three National Physician Sampling Frames.

Authors:  Catherine M DesRoches; Kirsten A Barrett; Bonnie E Harvey; Rachel Kogan; James D Reschovsky; Bruce E Landon; Lawrence P Casalino; Stephen M Shortell; Eugene C Rich
Journal:  J Gen Intern Med       Date:  2015-08       Impact factor: 5.128

2.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

Authors:  Michael W Drazer; Dezheng Huo; Scott E Eggener
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

3.  Physician Market Structure, Patient Outcomes, and Spending: An Examination of Medicare Beneficiaries.

Authors:  Thomas Koch; Brett Wendling; Nathan E Wilson
Journal:  Health Serv Res       Date:  2018-01-22       Impact factor: 3.402

Review 4.  When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.

Authors:  V Stavrinides; C C Parker; C M Moore
Journal:  Cancer Treat Rev       Date:  2017-05-23       Impact factor: 12.111

5.  Variation in the use of active surveillance for low-risk prostate cancer.

Authors:  Björn Löppenberg; David F Friedlander; Anna Krasnova; Andrew Tam; Jeffrey J Leow; Paul L Nguyen; Hawa Barry; Stuart R Lipsitz; Mani Menon; Firas Abdollah; Jesse D Sammon; Maxine Sun; Toni K Choueiri; Adam S Kibel; Quoc-Dien Trinh
Journal:  Cancer       Date:  2017-09-13       Impact factor: 6.860

6.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

7.  Predictors of patient preferences and treatment choices for localized prostate cancer.

Authors:  Benjamin D Sommers; Clair J Beard; Anthony V D'Amico; Irving Kaplan; Jerome P Richie; Richard J Zeckhauser
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

8.  Association of Financial Integration Between Physicians and Hospitals With Commercial Health Care Prices.

Authors:  Hannah T Neprash; Michael E Chernew; Andrew L Hicks; Teresa Gibson; J Michael McWilliams
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

9.  Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Authors:  Stacy Loeb; Yasin Folkvaljon; Caitlin Curnyn; David Robinson; Ola Bratt; Pär Stattin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

Review 10.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Authors:  Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell
Journal:  J Urol       Date:  2017-12-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.